|
|
Blood, 1 February 2008, Vol. 111, No. 3, pp. 1456-1463.
Prepublished online as a Blood First Edition Paper on November 16, 2007; DOI 10.1182/blood-2007-02-074716.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang1,
Emilian Racila2,
Ronald P. Taylor3, and
George J. Weiner1,2
1 Graduate Program in Immunology, University of Iowa, Iowa City;
2 Holden Comprehensive Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City;
3 The Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA
Antibody-dependent cellular cytotoxicity (ADCC) and complement fixation both appear to play a role in mediating antitumor effects of monoclonal antibodies (mAbs), including rituximab. We evaluated the relationship between rituximab-induced complement fixation, natural killer (NK)–cell activation, and NK cell–mediated ADCC. Down-modulation of NK- cell CD16 and NK-cell activation induced by rituximab-coated target cells was blocked by human serum but not heat-inactivated serum. This inhibition was also observed in the absence of viable target cells. C1q and C3 in the serum were required for these inhibitory effects, while C5 was not. An antibody that stabilizes C3b on the target cell surface enhanced the inhibition of NK-cell activation induced by rituximab-coated target cells. Binding of NK cells to rituximab-coated plates through CD16 was inhibited by the fixation of complement. C5-depleted serum blocked NK cell–mediated ADCC. These data suggest that C3b deposition induced by rituximab-coated target cells inhibits the interaction between the rituximab Fc and NK-cell CD16, thereby limiting the ability of rituximab-coated target cells to induce NK activation and ADCC. Further studies are needed to define in more detail the impact of complement fixation on ADCC, and whether mAbs that fail to fix complement will be more effective at mediating ADCC.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. M. Illidge, M. Bayne, N. S. Brown, S. Chilton, M. S. Cragg, M. J. Glennie, Y. Du, V. Lewington, J. Smart, J. Thom, et al.
Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
Blood,
February 12, 2009;
113(7):
1412 - 1421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Beers, M. S. Cragg, and M. J. Glennie
Response: Superior B cell-depleting activity of type II anti-CD20 mAb is not due to activation of complement
Blood,
November 15, 2008;
112(10):
4355 - 4356.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Beers, C. H. T. Chan, S. James, R. R. French, K. E. Attfield, C. M. Brennan, A. Ahuja, M. J. Shlomchik, M. S. Cragg, and M. J. Glennie
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
Blood,
November 15, 2008;
112(10):
4170 - 4177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Racila, B. K. Link, W.-K. Weng, T. E. Witzig, S. Ansell, M. J. Maurer, J. Huang, C. Dahle, A. Halwani, R. Levy, et al.
A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Clin. Cancer Res.,
October 15, 2008;
14(20):
6697 - 6703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. V. Beum, M. A. Lindorfer, and R. P. Taylor
Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving
J. Immunol.,
August 15, 2008;
181(4):
2916 - 2924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
